Therefore, by using the population-based reimbursement databases of the National Health Insurance (NHI) in Taiwan, the present study tests these hypotheses by evaluating the incidence and odds ratios of HP eradication in patients with T2DM versus non-diabetic subjects; and in insulin users versus non-users among the patients with T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.